Abstracts Archive - Page 2408 of 2605 - ACR Meeting Abstracts

Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
Abstract Number: 337 • 2013 ACR/ARHP Annual Meeting
Fatigue and Work Disability In Psoriatic Arthritis
Jessica Walsh¹, Molly McFadden², Gerald G. Krueger³, Allen D. Sawitzke¹ and Daniel O. Clegg⁴, ¹Rheumatology, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT
Background/Purpose: Fatigue and work disability (WD) are common in people with psoriatic arthritis (PsA). Pain and discomfort from PsA contribute to fatigue by impairing sleep…
Abstract Number: 338 • 2013 ACR/ARHP Annual Meeting
Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
Yasser El Miedany¹, Maha El Gaafary², Sally Youssef³ and Annie Nasr⁴, ¹Rheumatology, Medway Hospital, Gillingham, United Kingdom, ²Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt, ³Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁴Radiology, Ain Shams University, Cairo, Egypt
Background/Purpose: To evaluate the use of musculoskeletal US as a predictor for inflammatory structural progression in psoriatic patients Methods: Measures of association (OR) were tested,…
Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
Abstract Number: 300 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
Monalyn Labitigan¹, Asha Shrestha¹, George W. Reed^2,3, Robert P. Magner⁴, Nicole Jordan⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg⁷, Asena Bahce-Altuntas⁵ and Anna R. Broder¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²CORRONA, Inc., Southborough, MA, ³Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Psoriatic Arthritis (PsA) is linked to both obesity and an increased cardiovascular risk. However, the relationship between PsA disease activity and lipids, a major cardiovascular…
Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Odirlei Andre Monticielo¹, Karen Regina Rosso Schons², Cristiane Faccin Knob², Walter Neumaier², Maristela de Oliveira Beck² and André Avelino Costa Beber², ¹Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal de Santa Maria, Santa Maria, Brazil
Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…
Abstract Number: 302 • 2013 ACR/ARHP Annual Meeting
Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Christopher T. Ritchlin¹, Iain B. McInnes², Arthur Kavanaugh³, Lluis Puig⁴, Proton Rahman⁵, Carrie Brodmerkel⁶, Shu Li⁶, Yaung-Kaung Shen⁶, Mittie K. Doyle⁶, Alan M. Mendelsohn⁷ and Alice B. Gottlieb⁸, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of California, San Diego, La Jolla, CA, ⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸Tufts Medical Center, Boston, MA
Background/Purpose: Ustekinumab (UST) has demonstrated substantial efficacy and an acceptable safety profile, and is approved for use, in treating moderate-to-severe psoriasis. UST has also demonstrated…
Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Alexis Ogdie¹, Yiding Yu², Kevin Haynes³, Samantha Maliha⁴, Thorvardur Love^5,6, Andrea Troxel⁷, Sean Hennessy⁸, David Margolis⁹, Stephen Kimmel¹⁰, Nehal N. Mehta¹¹, Hyon Choi^12,13 and Joel Gelfand¹⁴, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Brigham and Women's Hospital, Boston, MA, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁶Landspitali University Hospital, Reykjavik, Iceland, ⁷Biostatistics and Epidemiology, University of Pennsylvania., Philadelphia, PA, ⁸Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹⁰Cardiology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹¹National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD, ¹²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA
Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…
Abstract Number: 304 • 2013 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance
Doquyen H. Huynh¹, Carol Etzel², Vanessa Cox³, J. M. Kremer⁴, Jeffrey D. Greenberg⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²CORRONA, Inc, Southborough, MA, ³General Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶University of California San Diego, San Diego, CA
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have been considered a relatively specific marker for rheumatoid arthritis (RA), and may play a role in its pathogenesis. In…
Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Devy Zisman^1,2, Haim Bitterman^1,3, Ilan Feldhamer⁴, Doron Comanesther⁴, Erez Battat⁴, Sari Greenberg-Dotan⁴, Sarit Cohen⁵ and Arnon-Dov Cohen⁴, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Medical Center, Haifa, Israel
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…
Abstract Number: 306 • 2013 ACR/ARHP Annual Meeting
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Maria Laura Acosta Felquer¹, Santiago Ruta¹, Javier Rosa², David A. Navarta³, Carla Saucedo¹, Ricardo Garcia-Monaco⁴, Mirtha Sabelli² and Enrique R. Soriano⁵, ¹Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Psoriatic arthritis (PsA) manifests clinically in several ways, including arthritis, enthesitis, and dactylitis,. Assessment of disease activity in PsA should ideally record each feature.…
Abstract Number: 307 • 2013 ACR/ARHP Annual Meeting
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Ralf G. Thiele¹, Yahui Grace Chiu¹, Francisco A. Tausk², Bethany A. Marston¹, Gregory Dieudonne³, Vaseem Chengazi³, Michelle Smith¹, Sharon Moorehead¹, Rick Barrett¹ and Christopher T. Ritchlin¹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Dermatology, University of Rochester, Rochester, NY, ³Radiology, University of Rochester, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by about 10 years in patients who develop psoriatic arthritis (PsA). Several studies have documented abnormal musculoskeletal imaging findings…
Abstract Number: 308 • 2013 ACR/ARHP Annual Meeting
Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
Roberto Ranza¹, Claudia G Schainberg², Sueli Carneiro³, Gladys Martins⁴, Jose Joaquim Rodrigues⁵, Jamille Carneiro⁶, Ricardo Romiti⁷, Thiago B. M. Barros⁸, Ana Luiza Sampaio⁹, Amanda Pedreira⁹, Carolina Z Costa¹⁰, Rogerio MC Pinto¹¹, M. Elaine Husni¹² and Abrar A. Qureshi¹³, ¹Universidade Federal de Uberlandia, Uberlandia MG, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁴Dermatologia Hospital Universitario Universidade de Brasilia, Brasilia, Brazil, ⁵Dermatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ⁶Reumatologia, Universidade de Brasilia, Brasilia, Brazil, ⁷Dermatologia Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁸Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Dermatologia Hospital Universitário e Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁰Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ¹¹Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil, ¹²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ¹³Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriatic Arthritis (PsA) remains an under-diagnosed disease among patients with psoriasis (PsO). Dermatologists are not routinely trained to detect musculoskeletal manifestations hence arthritis, enthesitis…
Abstract Number: 309 • 2013 ACR/ARHP Annual Meeting
Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis
Muhammad Haroon¹, Phil Gallagher² and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Diagnostic delay in Psoriatic Arthritis (PsA) is not uncommon with a recent study of psoriasis patients attending a dermatology clinic showing that 29% of…
Abstract Number: 310 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Dafna D. Gladman³, Adewale O. Adebajo⁴, Juan J. Gomez-Reino⁵, Jürgen Wollenhaupt⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁶Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].